Literature DB >> 25219814

Recurrent malignant gliomas.

John P Kirkpatrick1, John H Sampson2.   

Abstract

In almost all patients, malignant glioma recurs following initial treatment with maximal safe resection, conformal radiotherapy, and temozolomide. This review describes the many options for treatment of recurrent malignant gliomas, including reoperation, alternating electric field therapy, chemotherapy, stereotactic radiotherapy or radiosurgery, or some combination of these modalities, presenting the evidence for each approach. No standard of care has been established, though the antiangiogenic agent, bevacizumab; stereotactic radiotherapy or radiosurgery; and, perhaps, combined treatment with these 2 modalities appear to offer modest benefits over other approaches. Clearly, randomized trials of these options would be advantageous, and novel, more efficacious approaches are urgently needed.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25219814      PMCID: PMC4522935          DOI: 10.1016/j.semradonc.2014.06.006

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  99 in total

1.  Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection.

Authors:  Robert E Elliott; Erik C Parker; Stephen C Rush; Stephen P Kalhorn; Yaron A Moshel; Ashwatha Narayana; Bernadine Donahue; John G Golfinos
Journal:  World Neurosurg       Date:  2011 Jul-Aug       Impact factor: 2.104

2.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

3.  Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Authors:  Evanthia Galanis; S Keith Anderson; Jackie M Lafky; Joon H Uhm; Caterina Giannini; Shaji K Kumar; Teresa K Kimlinger; Donald W Northfelt; Patrick J Flynn; Kurt A Jaeckle; Timothy J Kaufmann; Jan C Buckner
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

4.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

5.  EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Authors:  Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 6.  Raising the bar: how HIF-1 helps determine tumor radiosensitivity.

Authors:  Benjamin J Moeller; Mark W Dewhirst
Journal:  Cell Cycle       Date:  2004-09-20       Impact factor: 4.534

7.  Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).

Authors:  Umut Demirci; Gulnihal Tufan; Bilge Aktas; Ozan Balakan; Ahmet Alacacioglu; Faysal Dane; Huseyin Engin; M Ali Kaplan; Yusuf Gunaydin; Nuriye Y Ozdemir; I Tugba Unek; Halit Karaca; Tulay Akman; Ozlem U Sonmez; Ugur Coskun; Hakan Harputluoglu; Alper Sevinc; Onder Tonyali; Suleyman Buyukberber; Mustafa Benekli
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-12       Impact factor: 4.553

8.  Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Authors:  Ulrik Lassen; Morten Sorensen; Tine Bernhardtsen Gaziel; Benedikte Hasselbalch; Hans Skovgaard Poulsen
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

9.  Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.

Authors:  David Y Lee; John L Chunta; Sean S Park; Jiayi Huang; Alvaro A Martinez; Inga S Grills; Sarah A Krueger; George D Wilson; Brian Marples
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-01       Impact factor: 7.038

10.  TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.

Authors:  Rosa S Schneiderman; Esther Shmueli; Eilon D Kirson; Yoram Palti
Journal:  BMC Cancer       Date:  2010-05-23       Impact factor: 4.430

View more
  22 in total

1.  Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).

Authors:  Pierina Navarria; Giuseppe Minniti; Elena Clerici; Stefano Tomatis; Valentina Pinzi; Patrizia Ciammella; Marco Galaverni; Dante Amelio; Daniele Scartoni; Silvia Scoccianti; Marco Krengli; Laura Masini; Lorena Draghini; Ernesto Maranzano; Valentina Borzillo; Paolo Muto; Fabio Ferrarese; Laura Fariselli; Lorenzo Livi; Francesco Pasqualetti; Alba Fiorentino; Filippo Alongi; Michela Buglione di Monale; Stefano Magrini; Marta Scorsetti
Journal:  J Neurooncol       Date:  2018-12-04       Impact factor: 4.130

2.  Nuclear Protein C23 on the Cell Surface Plays an Important Role in Activation of CXCR4 Signaling in Glioblastoma.

Authors:  Congxin Dai; Shunzeng Lv; Ranran Shi; Jing Ding; Xiao Zhong; Huishu Song; Xiaochen Ma; Jianzhen Fan; Bowen Sun; Renzhi Wang; Wenbin Ma
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

3.  Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.

Authors:  T Hundsberger; A F Hottinger; U Roelcke; P Roth; D Migliorini; P Y Dietrich; K Conen; G Pesce; E Hermann; A Pica; M W Gross; D Brügge; L Plasswilm; M Weller; P M Putora
Journal:  J Neurooncol       Date:  2015-10-12       Impact factor: 4.130

4.  Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism.

Authors:  Xiao Feng; Yang Yu; Sijia He; Jin Cheng; Yanping Gong; Zhengxiang Zhang; Xuguang Yang; Bing Xu; Xinjian Liu; Chuan-Yuan Li; Ling Tian; Qian Huang
Journal:  Cancer Lett       Date:  2016-11-05       Impact factor: 8.679

5.  Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas.

Authors:  Meryem Aktan; Mehmet Koc; Gul Kanyilmaz
Journal:  Ann Transl Med       Date:  2015-11

6.  Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.

Authors:  Baosheng Zhou; Guoyun Bu; Yipin Zhou; Yue Zhao; Wei Li; Mu Li
Journal:  Med Oncol       Date:  2014-11-30       Impact factor: 3.064

7.  Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis.

Authors:  Valentina Pinzi; Chiara Orsi; Marcello Marchetti; Ida Maddalena Milanesi; Livia Corinna Bianchi; Francesco DiMeco; Valeria Cuccarini; Mariangela Farinotti; Paolo Ferroli; Gaetano Finocchiaro; Angelo Franzini; MariaLuisa Fumagalli; Antonio Silvani; Laura Fariselli
Journal:  Neurol Sci       Date:  2015-03-25       Impact factor: 3.307

8.  The radiosurgery fractionation quandary: single fraction or hypofractionation?

Authors:  John P Kirkpatrick; Scott G Soltys; Simon S Lo; Kathryn Beal; Dennis C Shrieve; Paul D Brown
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

9.  Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model.

Authors:  Etienne Audureau; Anaïs Chivet; Renata Ursu; Robert Corns; Philippe Metellus; Georges Noel; Sonia Zouaoui; Jacques Guyotat; Pierre-Jean Le Reste; Thierry Faillot; Fabien Litre; Nicolas Desse; Antoine Petit; Evelyne Emery; Emmanuelle Lechapt-Zalcman; Johann Peltier; Julien Duntze; Edouard Dezamis; Jimmy Voirin; Philippe Menei; François Caire; Phong Dam Hieu; Jean-Luc Barat; Olivier Langlois; Jean-Rodolphe Vignes; Pascale Fabbro-Peray; Adeline Riondel; Elodie Sorbets; Marc Zanello; Alexandre Roux; Antoine Carpentier; Luc Bauchet; Johan Pallud
Journal:  J Neurooncol       Date:  2017-11-20       Impact factor: 4.130

10.  The involvement of anterior gradient 2 in the stromal cell-derived factor 1-induced epithelial-mesenchymal transition of glioblastoma.

Authors:  Chunhua Xu; Yue Liu; Limin Xiao; Changgui Guo; Shengze Deng; Suyue Zheng; Erming Zeng
Journal:  Tumour Biol       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.